Alzex Neuropharma Inc.
TRRI
$0.00
-$0.07-99.58%
OTC PK
| 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 3.96M | 3.79M | 3.69M | -- | -- |
| Total Other Revenue | 36.30K | 35.90K | 41.30K | -- | -- |
| Total Revenue | 4.00M | 3.82M | 3.73M | -- | -- |
| Cost of Revenue | 3.58M | 3.43M | 3.33M | -- | -- |
| Gross Profit | 420.80K | 388.60K | 407.00K | -- | -- |
| SG&A Expenses | 293.70K | 223.40K | 269.40K | -- | -- |
| Depreciation & Amortization | 66.30K | 68.00K | 70.80K | -- | -- |
| Other Operating Expenses | -45.80K | -45.80K | -45.80K | -- | -- |
| Total Operating Expenses | 3.89M | 3.68M | 3.62M | -- | -- |
| Operating Income | 106.60K | 143.10K | 112.80K | -- | -- |
| Income Before Tax | 95.60K | 117.80K | 79.80K | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.10 | 0.12 | 0.08 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.60K | 117.80K | 79.80K | -- | -- |
| EBIT | 106.60K | 143.10K | 112.80K | -- | -- |
| EBITDA | -48.90K | -10.90K | -65.40K | -- | -- |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |